ZSZhuqing Shi

Zhuqing Shi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhuqing Shi has a total of 80 co-authors. Here are the top co-authors by number of shared publications:

  • Brian T. Helfand

    Program for Genomic Translational Research, Endeavor Health, Evanston, IL (J.X., Z.S., H.T., J.W., A.A., S.L.Z., B.T.H.).

    10 shared publications
  • Jianfeng Xu

    Program for Personalized Cancer Care NorthShore University HealthSystem Evanston Illinois USA

    10 shared publications
  • Jun Wei

    Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, USA

    7 shared publications
  • S. Lilly Zheng

    Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, USA

    6 shared publications
  • Hongjie Yu

    Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, Illinois

    5 shared publications
  • W. Kyle Resurreccion

    Program for Personalized Cancer Care, NorthShore University HealthSystem, Evanston, USA

    4 shared publications

Latest Publications

  • Development of an Integrated Monogenic and Polygenic Risk Assessment Tool for Coronary Artery Disease and Its Application in a Community-Based Health Care Biobank

    by Jianfeng Xu, Zhuqing Shi, Sumeet A. Khetarpal, Ashley J. Mulford, Osama Siddiqui, Huy Tran, Jun Wei, Annabelle Ashworth, S. Lilly Zheng, David Duggan, et al.

    BACKGROUND: Current genetic testing for coronary artery disease (CAD) primarily targets monogenic variants in individuals with severe hypercholesterolemia. Whether supplementing monogenic testing with polygenic risk scores for CAD and Lp(a; lipoprotein[a]) levels [PRS Lp(a) ] improves identification of high-risk individuals in the general population remains understudied. METHODS: A genetic probability for CAD (GenProb CAD ), incorporating monogenic pathogenic variants (PVs), polygenic risk scores for CAD, and PRS Lp(a) was developed using Cox regression in 226 145 UK Biobank participants, validated in the remaining 226 145 UK Biobank participants, and applied to 20 477 participants of the Genomic Health Initiative, a community-based health care biobank. Predictive performance was evaluated and adjusted for clinical risk factors. RESULTS: In the UK Biobank development cohort, PVs, polygenic risk scores for CAD and PRS Lp(a) were each independently associated with CAD. In the UK Biobank validation cohort, GenProb CAD outperformed PVs and the polygenic risk score in predicting CAD and reclassified risk among PV carriers. GenProb CAD identified 16% of participants as high risk, 46-fold more than PV carriers (0.35%), with comparable observed CAD prevalence (15.60% versus 15.43%). Nearly 50% of CAD with high-risk GenProb CAD were premature. GenProb CAD also independently predicted incident CAD after adjusting for clinical risk factors. Importantly, high-risk individuals defined by GenProb CAD showed consistently elevated CAD incidence across all low-density lipoprotein cholesterol strata. When UK Biobank-derived coefficients and cutoffs were applied in the Genomic Health Initiative, GenProb CAD substantially outperformed the PV-only strategy, identifying 1966 high-risk participants (345 developed CAD), far exceeding the 20 PV carriers detected among those with low-density lipoprotein cholesterol ≥190 mg/dL (5 developed CAD). A universal genetic testing strategy using GenProb CAD would hypothetically identify 20.75% of all incident CAD, 69-fold higher than current monogenic testing (0.3%). Results were generally consistent across ancestry populations, although the sample size of non-European participants was limited. CONCLUSIONS: GenProb CAD , a novel integrated genetic risk tool combining monogenic PVs, polygenic risk scores for CAD, and PRS Lp(a) , improves identification of individuals at high genetic risk for CAD across diverse populations.

  • Inherited risk assessment and its clinical utility for predicting prostate cancer from diagnostic prostate biopsies

    by Jianfeng Xu, W. Kyle Resurreccion, Zhuqing Shi, Jun Wei, Chi-Hsiung Wang, S. Lilly Zheng, Peter J. Hulick, Ashley E. Ross, Christian P. Pavlovich, Brian T. Helfand, et al.

    Background Many studies on prostate cancer (PCa) germline variants have been published in the last 15 years. This review critically assesses their clinical validity and explores their utility in prediction of PCa detection rates from prostate biopsy. Methods An integrative review was performed to (1) critically synthesize findings on PCa germline studies from published papers since 2016, including risk-associated single nucleotide polymorphisms (SNPs), polygenic risk score methods such as genetic risk score (GRS), and rare pathogenic mutations (RPMs); (2) exemplify the findings in a large population-based cohort from the UK Biobank (UKB); (3) identify gaps for implementing inherited risk assessment in clinic based on experience from a healthcare system; (4) evaluate available GRS data on their clinical utility in predicting PCa detection rates from prostate biopsies; and (5) describe a prospective germline-based biopsy trial to address existing gaps. Results SNP-based GRS and RPMs in four genes (HOXB13, BRCA2, ATM, and CHEK2) were significantly and consistently associated with PCa risk in large well-designed studies. In the UKB, positive family history, RPMs in the four implicated genes, and a high GRS (>1.5) identified 8.12%, 1.61%, and 17.38% of men to be at elevated PCa risk, respectively, with hazard ratios of 1.84, 2.74, and 2.39, respectively. Additionally, the performance of GRS for predicting PCa detection rate on prostate biopsy was consistently supported in several retrospective analyses of transrectal ultrasound (TRUS)-biopsy cohorts. Prospective studies evaluating the performance of all three inherited measures in predicting PCa detection rate from contemporary multiparametric MRI (mpMRI)-based biopsy are lacking. A multicenter germline-based biopsy trial to address these gaps is warranted. Conclusions The complementary performance of three inherited risk measures in PCa risk stratification is consistently supported. Their clinical utility in predicting PCa detection rate, if confirmed in prospective clinical trials, may improve current decision-making for prostate biopsy.


  • KLK3 germline mutation I179T complements DNA repair genes for predicting prostate cancer progression

    by Jianfeng Xu, Zhuqing Shi, Jun Wei, Rong Na, W. Kyle Resurreccion, Chi-Hsiung Wang, Chris Sample, Misop Han, S. Lilly Zheng, Kathleen A. Cooney, et al.

    Background Germline mutations in DNA repair genes and KLK3 have been associated with adverse prostate cancer (PCa) outcomes in separate studies but never jointly. The objective of this study is to simultaneously assess these two types of germline mutations. Methods Germline rare pathogenic mutations (RPMs) in 9 commonly tested DNA repair genes and KLK3 variants were tested for their associations with PCa progression in two PCa cohorts: (1) hospital-based PCa patients treated with radical surgery at the Johns Hopkins Hospital (JHH, N = 1943), and (2) population-based PCa patients in the UK Biobank (UKB, N = 10,224). Progression was defined as metastasis and/or PCa-specific death (JHH) and PCa-specific death (UKB). RPMs of DNA repair genes were annotated using the American College of Medical Genetics recommendations. Known KLK3 variants were genotyped. Associations were tested using a logistic regression model adjusting for genetic background (top ten principal components). Results In the JHH, 3.2% (59/1,843) of patients had RPMs in 9 DNA repair genes; odds ratio (OR, 95% confidence interval) for progression was 2.99 (1.6–5.34), P < 0.001. In comparison, KLK3 I179T mutation was more common; 9.7% (189/1,943) carried the mutation, OR = 1.6 (1.05–2.37), P = 0.02. Similar results were found in the UKB. Both types of mutations remained statistically significant in multivariable analyses. In the combined cohort, compared to patients without any mutations (RPMs−/KLK3−), RPMs−/KLK3+ patients had modestly increased risk for progression [OR = 1.54 (1.15–2.02), P = 0.003], and RPMs+/KLK3+ patients had greatly increased risk for progression [OR = 5.41 (2.04–12.99), P < 0.001]. Importantly, associations of mutations with PCa progression were found in patients with clinically defined low- or intermediate risk for disease progression. Conclusions Two different cohorts consistently demonstrate that KLK3 I179T and RPMs of nine commonly tested DNA repair genes are complementary for predicting PCa progression. These results are highly relevant to PCa germline testing and provide critical information for KLK3 I179T to be considered in guidelines.


  • Association of germline rare pathogenic mutations in guideline‐recommended genes with prostate cancer progression: A meta‐analysis

    by Zhuqing Shi, Lucy Lu, William Kyle Resurreccion, Wancai Yang, Jun Wei, Qiang Wang, Valentina Engelmann, Siqun Lilly Zheng, Kathleen A. Cooney, William B. Isaacs, et al.

    Background: Germline mutations in several genes, mainly DNA repair genes, have been associated with prostate cancer (PCa) progression. However, primarily due to the rarity of mutations, statistical evidence for these associations is not consistently established. The objective of this study is to synthesize evidence from multiple studies using a meta‐analysis.Methods: Genes analyzed were chosen based on National Comprehensive Cancer Network guidelines recommendations (10 genes) and a commonly reported gene (NBN). PCa progression in this analysis was defined as either having metastases or PCa‐specific mortality. We searched PubMed for papers published before April 26, 2021, using selected keywords. Pooled odds ratio (OR) was estimated in all races and Caucasians‐only using both fixed‐ and random‐effect models.Results: The search identified 1028 papers and an additional five from a manual review of references. After a manual process that excluded noneligible studies, 11 papers remained, including a total of 3944 progressors and 20,054 nonprogressors. Combining results from these eligible studies, mutation carrier rates were significantly higher in progressors than nonprogressors for NBN, BRCA2, ATM (under both fixed‐ and random‐effect models), for CHEK2 (under fixed‐effect model only), and for PALB2 (under random‐effect model only), p < 0.05. Pooled OR (95% confidence interval) was 6.38 (2.25–18.05), 3.41 (2.31; 5.03), 1.93 (1.17–3.20), and 1.53 (1.00–2.33) for NBN, BRCA2, ATM, and CHEK2, respectively, under fixed‐effect model and 2.63 (1.12–6.13) for PALB2 under random‐effect model. No significant association was found for the six remaining genes. Certainty of evidence was low for many genes due primarily to the limited number of eligible studies and mutation carriers.Conclusions: Statistical evidence for five genes was obtained in this first meta‐analysis of germline mutations and PCa progression. While these results may help urologists and genetic counselors interpret germline testing results for PCa progression, more original studies are needed.


  • Observed evidence for guideline‐recommended genes in predicting prostate cancer risk from a large population‐based cohort

    by Jun Wei, Wancai Yang, Zhuqing Shi, Lucy Lu, Qiang Wang, W. Kyle Resurreccion, Valentina Engelmann, S. Lilly Zheng, Peter J. Hulick, Kathleen A. Cooney, et al.

    Background: Germline testing for prostate cancer (PCa) is now recommended by the National Comprehensive Cancer Network. While multi‐gene testing has been proposed, evidence for their association with PCa risk is not well established.Methods: We tested associations of pathogenic/likely pathogenic mutations in 10 guideline‐recommended genes (ATM, BRCA1, BRCA2, CHEK2, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13) with PCa risk in the UK Biobank, a population‐based cohort. Mutations were annotated based on prostate‐specific transcripts using the American College of Medical Genetics and Genomics standards. Associations were tested in 4399 PCa cases and 85,403 unaffected male controls using logistic regression adjusting for age and genetic background. p < .005 was considered significant based on Bonferroni correction.Results: Among the 10 tested genes, significantly higher mutation carrier rates in PCa cases versus controls were found for four genes at p < .005; HOXB13, BRCA2, ATM, and CHEK2, with odds ratios (95% confidence interval) estimated at 4.96 (3.62–6.69), 3.23 (2.23–4.56), 2.95 (2.01–4.22), 1.94 (1.43–2.58), respectively. No significant association was found between mutation carrier status and age at PCa diagnosis or family history of PCa. Despite the large sample size of this study, statistical power remains limited, especially for genes where pathogenic mutation carrier rates are extremely rare (<0.03%).Conclusion: Observed evidence for PCa risk was found for four of the 10 guideline‐recommended genes in this large population‐based study. Mutations in these four genes can be interpreted with confidence in genetic counseling for PCa risk assessment. Evidence for the remaining six genes needs to be further evaluated in larger studies.


  • Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients

    by Jianfeng Xu, William B. Isaacs, Mufaddal Mamawala, Zhuqing Shi, Patricia Landis, Jacqueline Petkewicz, Jun Wei, Chi‐Hsiung Wang, W. Kyle Resurreccion, Rong Na, et al.

    Background: Prostate cancer (PCa) is characterized by its tendency to be multifocal. However, few studies have investigated the endogenous factors that explain the multifocal disease. The primary objective of the current study is to test whether inherited PCa risk is associated with multifocal tumors in PCa patients.Methods: Subjects in this study were PCa patients of European ancestry undergoing active surveillance at Johns Hopkins Hospital (N = 805) and NorthShore University HealthSystem (N = 432). The inherited risk was measured by genetic risk score (GRS), an odds ratio‐weighted and population‐standardized polygenic risk score based on known risk‐associated single nucleotide polymorphisms. PCa multifocality was indirectly measured by the number and laterality of positive tumor cores from a 12‐core systematic biopsy.Results: In the combined cohort, 35.7% and 66.3% of patients had ≥2 tumor cores at the initial diagnostic biopsy and on at least one subsequent surveillance biopsy, respectively. For tumor laterality, 7.8% and 47.8% of patients had bilateral tumor cores at diagnostic and surveillance biopsies, respectively. We found, for the first time, that patients with higher numbers of positive cores at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values; p = .01 and p = 5.94E−04. Additionally, patients with bilateral tumors at diagnostic and surveillance biopsies, respectively, had significantly higher mean GRS values than those with unilateral tumors; p = .04 and p = .01. In contrast, no association was found between GRS and maximum core length of tumor or tumor grade at diagnostic/surveillance biopsies (all p > .05). Finally, we observed a modest trend that patients with higher GRS quartiles had a higher risk for tumor upgrading on surveillance biopsies. The trend, however, was not statistically significant (p > .05).Conclusions: The associations of GRS with two measurements of PCa multifocality (core numbers and laterality) provide novel and consistent evidence for the link between inherited PCa risk and multifocal tumors.


  • Open Access

    Validation of a prostate cancer polygenic risk score

    by Mary H. Black, Shuwei Li, Holly LaDuca, Min‐Tzu Lo, Jefferey Chen, Robert Hoiness, Stephanie Gutierrez, Brigette Tippin‐Davis, Hsiao‐Mei Lu, Marta Gielzak, et al.

    Background: Genome‐wide association studies have identified over 100 single‐nucleotide polymorphisms (SNPs) associated with prostate cancer (PrCa), and polygenic risk scores (PRS) based on their combined genotypes have been developed for risk stratification. We aimed to assess the contribution of PRS to PrCa risk in a large multisite study.Methods: The sample included 1972 PrCa cases and 1919 unaffected controls. Next‐generation sequencing was used to assess pathogenic variants in 14 PrCa‐susceptibility genes and 72 validated PrCa‐associated SNPs. We constructed a population‐standardized PRS and tested its association with PrCa using logistic regression adjusted for age and family history of PrCa.Results: The mean age of PrCa cases at diagnosis and age of controls at testing/last clinic visit was 59.5 ± 7.2 and 57.2 ± 13.0 years, respectively. Among 1740 cases with pathology data, 57.4% had Gleason score ≤ 6, while 42.6% had Gleason score ≥ 8. In addition, 39.6% cases and 20.1% controls had a family history of PrCa. The PRS was significantly higher in cases than controls (mean ± SD: 1.42 ± 1.11 vs 1.02 ± 0.76; P < .0001). Compared with men in the 1st quartile of age‐adjusted PRS, those in the 2nd, 3rd, and 4th quartile were 1.58 (95% confidence interval [CI]: 1.31‐1.90), 2.36 (95% CI: 1.96‐2.84), and 3.98 (95% CI: 3.29‐4.82) times as likely to have PrCa (all P < .0001). Adjustment for family history yielded similar results. PRS predictive performance was consistent with prior literature (area under the receiver operating curve = 0.64; 95% CI: 0.62‐0.66).Conclusions: These data suggest that a 72‐SNP PRS is predictive of PrCa, supporting its potential use in clinical risk assessment.


  • Broad‐ and narrow‐sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

    by Hongjie Yu, Zhuqing Shi, Xiaoling Lin, Quanwa Bao, Haifei Jia, Jun Wei, Brian T. Helfand, Siqun. L. Zheng, David Duggan, Daru Lu, et al.

    Background: Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied.Methods: We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad‐sense validity) and score values (narrow‐sense validity).Results: A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk‐associated SNPs. For broad‐sense validity in the testing population, higher deciles were significantly associated with higher observed risk; Ptrend was 7.40 × 10−11, 7.64 × 10−13, and 7.51 × 10−10 for GRS, P + T, and LDpred, respectively. For narrow‐sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively.Conclusions: The performance of GRS was better than P + T and LDpred. Fewer and well‐established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.


  • Concept and benchmarks for assessing narrow‐sense validity of genetic risk score values

    by Hongjie Yu, Zhuqing Shi, Yishuo Wu, Chi‐Hsiung Wang, Xiaoling Lin, Chelsea Perschon, William B. Isaacs, Brian T. Helfand, S. Lilly Zheng, David Duggan, et al.

    Background: While higher genetic risk score (GRS) has been statistically associated with increased disease risk (broad‐sense validity), the concept and tools for assessing the validity of reported GRS values from tests (narrow‐sense validity) are underdeveloped.Methods: We propose two benchmarks for assessing the narrow‐sense validity of GRS. The baseline benchmark requires that the mean GRS value in a general population approximates 1.0. The calibration benchmark assesses the agreement between observed risks and estimated risks (GRS values). We assessed benchmark performance for three prostate cancer (PCa) GRS tests, derived from three SNP panels with increasing stringency of selection criteria, in a PCa chemoprevention trial where 714 of 3225 men were diagnosed with PCa during the 4‐year follow‐up.Results: GRS from Panels 1, 2, and 3 were all statistically associated with PCa risk; P = 5.58 × 10−3, P = 1 × 10−3, and P = 1.5 × 10−13, respectively (broad‐sense validity). For narrow‐sense validity, the mean GRS value among men without PCa was 1.33, 1.09, and 0.98 for Panels 1, 2, and 3, respectively (baseline benchmark). For assessing the calibration benchmark, observed risks were calculated for seven groups of men with GRS values <0.3, 0.3–0.79, 0.8–1.19, 1.2‐1.49, 1.5‐1.99, 2‐2.99, and ≥3. The calibration slope (higher is better) was 0.15, 0.12, and 0.60, and the bias score (lower is better) between the observed risks and GRS values was 0.08, 0.08, and 0.02 for Panels 1, 2, and 3, respectively.Conclusion: Performance differed considerably among GRS tests. We recommend that all GRS tests be evaluated using the two benchmarks before clinical implementation for individual risk assessment.


  • Open Access

    Systematic evaluation of cancer‐specific genetic risk score for 11 types of cancer in The Cancer Genome Atlas and Electronic Medical Records and Genomics cohorts

    by Zhuqing Shi, Hongjie Yu, Yishuo Wu, Xiaoling Lin, Quanwa Bao, Haifei Jia, Chelsea Perschon, David Duggan, Brian T. Helfand, Siqun L. Zheng, et al.

    Background: Genetic risk score (GRS) is an odds ratio (OR)‐weighted and population‐standardized method for measuring cumulative effect of multiple risk‐associated single nucleotide polymorphisms (SNPs). We hypothesize that GRS is a valid tool for risk assessment of most common cancers.Methods: Utilizing genotype and phenotype data from The Cancer Genome Atlas (TCGA) and Electronic Medical Records and Genomics (eMERGE), we tested 11 cancer‐specific GRSs (bladder, breast, colorectal, glioma, lung, melanoma, ovarian, pancreatic, prostate, renal, and thyroid cancer) for association with the respective cancer type. Cancer‐specific GRSs were calculated, for the first time in these cohorts, based on previously published risk‐associated SNPs using the Caucasian subjects in these two cohorts.Results: Mean cancer‐specific GRS in the population controls of eMERGE approximated the expected value of 1.00 (between 0.98 and 1.02) for all 11 types of cancer. Mean cancer‐specific GRS was consistently higher in respective cancer patients than controls for all 11 types of cancer (P < 0.05). When subjects were categorized into low‐, average‐, and high‐risk groups based on cancer‐specific GRS (1.5, respectively), significant dose‐response associations of higher cancer‐specific GRS with higher OR of respective type of cancer were found for nine types of cancer (P‐trend < 0.05). More than 64% subjects in the population controls of eMERGE can be classified as high risk for at least one type of these cancers.Conclusion: Validity of GRS for predicting cancer risk is demonstrated for most types of cancer. If confirmed in larger studies, cancer‐specific GRS may have the potential for developing personalized cancer screening strategy.